JACKSONVILLE, Fla.—Johnson & Johnson Vision yesterday announced it has received U.S. Food & Drug Administration (FDA) clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th Annual AOSA Conference: Optometry’s Meeting 2022 in Chicago. The new contact lenses were developed to provide all day comfort and visual clarity amidst feedback from eyecare professionals and patients that today’s modern lifestyles, long hours and increased use of digital devices are taking a toll on eye comfort, Johnson & Johnson Vision said.

The company cited a recent survey that found that 71 percent of eyecare professionals are seeing patients who are experiencing eye discomfort related to increased screen-time, with young contact lens wearers spending an average of nine hours per day in front of a screen, causing them to blink less and experience more dryness and eye fatigue.
“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” said Peter Menziuso, company group chairman, Johnson & Johnson Vision. As pioneers in eye health, we’re leading with high science and deep clinical expertise to innovate for those moments that matter. Acuvue Oasys Max 1-Day is the latest in our long heritage of leading-edge innovation and we look forward to bringing this solution for patients experiencing ever-demanding lifestyles and environments.”
Available in spherical and multifocal, Acuvue Oasys Max 1-Day contact lenses are designed to address multiple vision correction needs, according to Johnson & Johnson Vision. The company is releasing them as a premium range of daily disposable contact lenses. The new lenses are anticipated to be available in the U.S., Canada and multiple European countries in the autumn, Johnson & Johnson Vision said.